Global Irritable Bowel Syndrome Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Irritable Bowel Syndrome Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Irritable bowel syndrome (IBS) is a gastrointestinal disorder that affects large intestine, symptom includes abdominal pain, altered bowel habits, increased gas, bloating (distention), cramping, and food intolerance. Moreover, these symptoms occur over long period for time. IBS is classified in three different types, IBS with constipation, IBS with diarrhea and IBS with alternating constipation & diarrhea.

Market Overview:

The latest research study on the global Irritable Bowel Syndrome market finds that the global Irritable Bowel Syndrome market reached a value of USD 1437.85 million in 2022. It’s expected that the market will achieve USD 2510.56 million by 2028, exhibiting a CAGR of 9.73% during the forecast period.

Region Overview:

From 2023-2028, North America is estimated to witness robust growth prospects.

Company Overview:

Bausch Health Companies Inc. is one of the major players operating in the Irritable Bowel Syndrome market, holding a share of 18.42% in 2019.

Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women’s health, and anti-infective therapeutic products.

Segmentation Overview:

Among different product types, Diarrhea-predominant (IBS-D) segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the Women segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Irritable Bowel Syndrome market covered in Chapter 3:

Sucampo
Astellas
Sebela Pharmaceuticals
Bausch Health Companies Inc.
Takeda
AstraZeneca
Ironwood Pharmaceuticals
Allergan

In Chapter 4 and Chapter 14.2, on the basis of types, the Irritable Bowel Syndrome market from 2018 to 2029 is primarily split into:

Diarrhea-predominant (IBS-D)
Constipation-predominant (IBS-C)
Mixed-presentation (IBS-M)

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Irritable Bowel Syndrome market from 2018 to 2029 covers:

Women
Men

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)